PubRank

S Sherry

Author PubWeight™ 106.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001 42.18
2 THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS. J Clin Invest 1949 8.50
3 Thrombolytic therapy: current status (1). N Engl J Med 1988 5.44
4 THE VITAMIN C REQUIREMENT OF MAN. ESTIMATED AFTER PROLONGED STUDIES OF THE PLASMA CONCENTRATION AND DAILY EXCRETION OF VITAMIN C IN 3 ADULTS ON CONTROLLED DIETS. J Clin Invest 1939 2.43
5 Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest 1969 1.52
6 Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol 1974 1.51
7 Thrombolytic therapy: current status (2). N Engl J Med 1988 1.49
8 The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med 1969 1.45
9 Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies. Am J Med 1971 1.41
10 Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest 1969 1.34
11 Current status of antithrombotic therapy in cardiovascular disease. Prog Cardiovasc Dis 1977 1.31
12 The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry 1966 1.31
13 THE MECHANISM OF THE EXCRETION OF VITAMIN C BY THE HUMAN KIDNEY AT LOW AND NORMAL PLASMA LEVELS OF ASCORBIC ACID. J Clin Invest 1940 1.30
14 Comparative activity of thrombin on substituted arginine and lysine esters. Am J Physiol 1965 1.28
15 Fibrinolysis. Annu Rev Med 1968 1.20
16 Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility. Biochemistry 1967 1.17
17 Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. J Am Coll Cardiol 1992 1.07
18 Chronic intravascular coagulation syndrome. N Engl J Med 1968 1.06
19 Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction: acute and follow-up studies. Am J Cardiol 1984 1.03
20 Nightmares and trauma: a comparison of nightmares after combat with lifelong nightmares in veterans. Am J Psychiatry 1984 0.99
21 Editorial: Lwo=dose heparin prophylaxis for postoperative venous thromboembolism. N Engl J Med 1975 0.98
22 Coronary thrombolysis for evolving myocardial infarction. Drugs 1984 0.96
23 Effect of urokinase antiserum on plasminogen activators: demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase. J Clin Invest 1968 0.95
24 Tissue plasminogen activator (t-PA). Will it fulfill its promise? N Engl J Med 1985 0.92
25 High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation. Am J Cardiol 1986 0.88
26 Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. Drugs 1980 0.88
27 The urokinase-pulmonary embolism trial. Circulation 1969 0.88
28 High-dose, brief intravenous streptokinase early in acute myocardial infarction. Am Heart J 1982 0.87
29 Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. Am J Med 1987 0.87
30 Immunoelectrophoretic characterization of plasma fibrinogen derivatives in patients with pathological plasma proteolysis. J Lab Clin Med 1967 0.87
31 [Activity of plasmin and streptokinase-activator on substituted arginine and lysine esters]. Thromb Diath Haemorrh 1966 0.87
32 Controlled trial of low-dose heparin and sulfinpyrazone to prevent venous thromboembolism after operation on the hip. J Bone Joint Surg Am 1978 0.86
33 Isolation and characterization of the clottable low molecular weight fibrinogen derived by limited plasmin hydrolysis of human fraction I-4. Biochemistry 1969 0.86
34 Clinical trials with antithrombotic and thrombolytic agents. Principles and pitfalls. Thromb Diath Haemorrh 1973 0.86
35 Clinical aspects of antiplatelet therapy. Semin Hematol 1985 0.86
36 Observations on the spontaneous arginine and lysine esterase activity of human plasma, and their relation to Hageman factor. Thromb Diath Haemorrh Suppl 1966 0.86
37 Clinical management of the thrombosed vessel: an overview. Angiology 1982 0.85
38 Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? Am J Cardiol 1987 0.84
39 NCBI genetic resources supporting immunogenetic research. Rev Immunogenet 2000 0.84
40 The purification of fibrinogen degradation products by pevikon block electrophoresis. Thromb Diath Haemorrh 1969 0.84
41 The urokinase-streptokinase pulmonary embolism trial (phase II) results. Circulation 1974 0.83
42 In vivo transformation between fibrinogens of varying ethanol solubilities: a pathway of fibrinogen catabolism. J Lab Clin Med 1969 0.83
43 Thrombosis prevention. N Engl J Med 1971 0.82
44 Fibrinolysis and afibrinogenemia. Anesthesiology 1966 0.81
45 Pharmacology and pharmacokinetics of platelet-active drugs under current clinical investigation. Adv Prostaglandin Thromboxane Leukot Res 1982 0.80
46 Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986 0.80
47 Intra-arterial thrombolytic therapy in peripheral vascular disease. Surg Gynecol Obstet 1987 0.80
48 Reaction of plasmic degradation products of fibrinogen in the radioimmunoassay of human fibrinopeptide A. Blood 1975 0.79
49 The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study. Thromb Diath Haemorrh 1975 0.79
50 Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J 1981 0.79
51 Fibrinolytic mechanisms in tissue injury. Gastroenterology 1966 0.79
52 Streptokinase therapy for thromboembolic occlusive vascular disease. Ann Intern Med 1971 0.79
53 Frustrations with clinical trials. Eur J Clin Pharmacol 1980 0.79
54 The proteolysis of fibrinogen by plasmin: the identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally. J Lab Clin Med 1966 0.78
55 The status of information about the use of blood, blood substitutes, and adjuvant solutions for extracorporeal circulation. Transfusion 1967 0.78
56 The problem of thromboembolic disease. Semin Nucl Med 1977 0.78
57 The anturane reinfarction trial. Circulation 1980 0.77
58 The current and future use of thrombolytic therapy. Annu Rev Pharmacol Toxicol 1985 0.77
59 A fibrinolytic defect in the respiratory distress syndrome. N Engl J Med 1990 0.75
60 Role of platelet-active drugs in coronary artery disease. Cardiovasc Clin 1983 0.75
61 Thrombolytic agents for acute evolving myocardial infarction: comparative effects. Ration Drug Ther 1987 0.75
62 Urokinase in thromboembolic disease: Pulmonary embolism. Am Heart J 1975 0.75
63 The venous system and the lung. Heart Lung 1978 0.75
64 Current developments in thrombolytic therapy. Thromb Diath Haemorrh Suppl 1973 0.75
65 Preventing pulmonary embolism with heparin in low doses. Postgrad Med 1976 0.75
66 The relationship of platelet coagulant activities to venous thrombosis following hip surgery. Br J Haematol 1976 0.75
67 Altered coagulability in tumor patients: introduction. Ann N Y Acad Sci 1974 0.75
68 [Sulfinpyrazone in the prevention of sudden death after myocardial infarction (author's transl)]. MMW Munch Med Wochenschr 1980 0.75
69 The fibrinolytic system and its pharmacologic activation for thrombolysis. Cardiol Clin 1987 0.75
70 Perspectives: fibrinolysis and thrombolysis. Thromb Diath Haemorrh Suppl 1966 0.75
71 Report of the subcommittee on fibrinolysis and thrombolysis. Thromb Diath Haemorrh Suppl 1968 0.75
72 The rt-PA versus streptokinase controversy--III. J Am Coll Cardiol 1992 0.75
73 Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1). Circulation 1970 0.75
74 [The Anturan reinfarct study]. Wien Med Wochenschr Suppl 1980 0.75
75 Fibrinolytic agents. Dis Mon 1969 0.75
76 Thrombolytic therapy for acute myocardial infarction. Am Heart J 1972 0.75
77 Interrelationships between platelets and coagulation in the pathogenesis of venous thrombosis. S Afr Med J 1976 0.75
78 Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes. Adv Prostaglandin Thromboxane Leukot Res 1982 0.75
79 Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits. J Am Coll Cardiol 1991 0.75
80 A tribute to Kenneth M. Brinkhous, M.D. Thromb Haemost 1979 0.75
81 Revisiting the development of thrombolytic therapy: an historical perspective. Trans Stud Coll Physicians Phila 1989 0.75
82 Fibrinolysis in health and disease. Med Times 1967 0.75
83 Thrombolytic therapy in surgical patients. Curr Surg 1981 0.75
84 Thrombosis. Circulation 1969 0.75
85 Thrombolytic agents. Annu Rev Pharmacol 1966 0.75
86 Low-dose heparin for the prophylaxis of pulmonary embolism. Am Rev Respir Dis 1976 0.75
87 Prospects in antithrombotic therapy. Am J Cardiol 1972 0.75
88 Thomas Morton Durant 1905-1977. Trans Assoc Am Physicians 1978 0.75
89 Report of the Subcommittee on Fibrinolysis and Thrombolysis. Thromb Diath Haemorrh Suppl 1967 0.75
90 Diabetes mellitus: a frequent factor in liability claims. N J Med 1994 0.75
91 Platelet coagulant activities and venous thrombosis after hip surgery. Trans Assoc Am Physicians 1974 0.75
92 Streptokinase. N Engl J Med 1969 0.75
93 The Anturane reinfarction trial. Thromb Haemost 1979 0.75
94 Thrombo-embolism. Proc Inst Med Chic 1977 0.75
95 Current concepts of the relationship of thrombosis and thrombolysis. Res Publ Assoc Res Nerv Ment Dis 1966 0.75
96 Thrombolysis by urokinase. J Atheroscler Res 1969 0.75
97 Observations on the plasma kallikreinogen (prekallikrein)-kallikrein enzyme system. Trans Assoc Am Physicians 1968 0.75
98 William Smith Tillett. 1892-1974. Trans Assoc Am Physicians 1975 0.75
99 Current status of thrombolytic therapy. Heart Lung 1978 0.75
100 Anticoagulant therapy: questions and answers. Compr Ther 1976 0.75
101 Urokinase. Ann Intern Med 1968 0.75
102 Drug trials in myocardial infarction. Lessons to be learned from the Anturane Reinfarction Trial. Eur J Clin Pharmacol 1980 0.75